National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

WT1 126-134 peptide vaccine
A synthetic peptide vaccine consisting of the amino acids 126 through 134 of the human Wilms' Tumor protein-1 (WT1) with potential antitumor activity. WT1, a tumor associated antigen, is overexpressed in most types of leukemia and in a variety of solid cancers. Vaccination with WT1 126-134 peptide vaccine may induce a WT1-specific cytotoxic T-lymphocyte (CTL) response against WT1 expressing cells, resulting in cell lysis and inhibition of cancer cell proliferation. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)




Previous:Wellbutrin, Wellcovorin, white button mushroom extract, Winobanin, WinRho SDF
Next:WT1-A10/AS01B immunotherapeutic GSK2130579A, WT1-sensitized T cells, Wymox, xaliproden hydrochloride, Xanax

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov